Divis Laboratories Ltd (DIVISLAB) Q2 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Divi's Laboratories manufactures active pharmaceutical ingredients, intermediates and specialty chemicals across its Generics and Custom Synthesis segments, plus a growing nutraceuticals business, with exports at 89% of FY26 revenue. The Q2 print will speak to whether the FY27 double-digit revenue growth guide holds against a soft year-ago base, and whether gross margin settles toward the ~60% full-year guide after Q1's ~68% was flattered by a ~₹500 Cr inventory build.

Divis Laboratories Ltd Q2 Results Date and Time

Per the board meeting intimation filed under Regulation 29 on Oct 22, 2026, the board is scheduled to meet on Saturday, Nov 07, 2026. The meeting will approve the unaudited standalone and consolidated results for Q2 and the half-year ended Sep 30, 2026.

A conference call is scheduled the same day, Nov 07, 2026, at 14:00 hrs IST, following the results release. Dial-in numbers are +91 22 6280 1526 / +91 22 7115 8341, with DiamondPass confirmation number 3977234. The transcript will be posted on www.divislabs.com.

What to expect from Divis Laboratories Ltd's Q2 FY27 results

The quarter's thesis rests on whether Divi's can extend its growth run against a soft Q2 FY26 base of Rs. 2,860 Cr total income, with management having reaffirmed double-digit revenue growth for FY27 on the Q1 call. Sector demand signals accelerated through the quarter — India's bulk drugs and intermediates exports grew 14.62% YoY in September 2026 to $509.25 mn, with H1 FY27 export value up 11.74% in USD — while the company entered the print on a record 60% custom synthesis mix and Q1 standalone constant-currency growth of 10%.

On costs, the Q1 solvent spike moderated, with Q2-to-date chemical prices 'sharply lower than Q1FY27 levels', but freight remains a live headwind: the Drewry WCI sat at $4,429/40ft on Oct 29, still far above the $1,899 pre-war level, and Hormuz disruption continued into early November.

Management has guided FY27 gross margin at approximately 60% and EBITDA margin 'similar as last year', cautioning that margins are lumpy and should be judged yearly — so the test this quarter is whether Q2 holds up as Q1's ~₹500 Cr inventory build and 60% CS mix roll off. The weaker rupee, which sat around 95.9–96.6/USD at end-September versus 94.66 on Jun 30, is directionally supportive for a book with 89% export revenue, against Q1's net forex loss of ₹7 Cr.

Key Things To Watch

FY27 guidance tracking: Management's stated FY27 markers and where each stands.

• Revenue growth — double-digit growth for FY27 — reaffirmed on the Q1 FY27 call: 'we are looking at double-digit growth'
• EBITDA margin — 'similar as last year' for FY27 — Q1 FY27 PBT margin of 37.53% was flattered by the 60% CS mix and the ₹500 Cr inventory build; analyst-adjusted EBITDA margin was 28–30%
• Gross margin — approximately 60% for FY27 — Q1 ran ~68% but management said 'not consistent throughout the year... Next quarter could be lower or higher'
• Capex — 'constant' for FY27 vs FY26's ₹2,500 Cr (24% of sales), barring major new CS projects

Custom Synthesis ramp and generic launches: Commercialisation milestones due over the next 12 months.

• Three dedicated CS projects — commercial volumes expected in Q3 or Q4 of calendar year 2027, contingent upon timely regulatory approvals; watch validation, customer submission and USFDA/EDQM approval updates
• Brivaracetam and Ticagrelor — commercial volumes expected in 3–6 months from Aug 2026, with 4 DMFs filed and validation quantities supplied
• Broader CS pipeline — 'close to about 18 to 20 projects are actually commercialized or being commercialized'; volume discussions flagged for H2 FY27 contingent on regulatory clearance

Generics pricing, solvent/freight costs and inventory: The cost and pricing overhangs management has flagged.

• Generics pricing — no improvement expected 'in at least the next two quarters' (stated Q2 FY26) and 'too early' to call (Q3 FY26); check whether pressure eases
• West Asia logistics — elevated ocean and air freight, port congestion and blank sailings; the 3-month rolling inventory strategy continues 'as long as broader macro market uncertainty persists'
• Inventory trajectory — whether the ~₹500 Cr Q1 FY27 build (vs a usual ₹50–100 Cr quarterly run rate) reverses or persists, and its margin impact

Kakinada Phase 2 and Unit 3 qualification: Capex and backward-integration decisions that could break the 'constant capex' guide.

• Kakinada Phase 2 — 4 production blocks under evaluation and decision-making; 'as and when they are finalized and on the paper, we will let you know'
• Unit 3 regulatory clearances — commercial qualification expected to take 1–2 years after validation; GMP/DMF qualification expected 'within the next few quarters' (stated Q2 FY26)
• Kakinada expansion — ₹1,500 crores plan with ₹600 crores capitalized as of Q4 FY26; ~70% of the announced ₹2,000 crores three-program capex capitalized as of Q1 FY27